All In Biotech

Drug Trial Radar · NCT07206225

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

294

Planned (sponsor's estimate)

Start

Nov 6, 2025

Primary completion

Jan 29, 2030

Study completion Jan 28, 2033

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin. For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial participation for each participant will vary as long-term follow-up will continue after treatment discontinuation until loss to-follow-up or death, or until the study is stopped by the sponsor.

Conditions

  • Non-muscle Invasive Bladder Cancer

Interventions

  • PF-08052667Drug

    PF-08052667 will be administered intravesical (IVe) instillation following a PF-02921367 (DDM) bladder pre-wash

  • SasanlimabDrug

    Sasanlimab will be administered as subcutaneous (SC) injection

  • BCGDrug

    BCG will be administered intravesical (IVe) instillation

  • PF-02921367Drug

    PF-02921367 (DDM) is a 10-min pre- wash and will be administered intravesical (IVe) instillation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants onlyTime frame: Day of first dose (Day 1) Up to 21 days
  2. Number of participants with adverse events (AEs) in Part 1 and Part 2 participants onlyTime frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
  3. Number of participants with laboratory abnormalities in Part 1 and Part 2 participants onlyTime frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
  4. Recurrence-free survival (RFS) in Part 3 participants onlyTime frame: Through end of study and up to approximately 2 years
  5. Event-free survival (EFS) in Part 3 participants onlyTime frame: Through end of study and up to approximately 2 years

Locations

69 sites in 6 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama · Recruiting

  • UAB Infusion Therapy Extended Care Clinic (ECC)

    Birmingham, Alabama · Recruiting

  • The University of Alabama at Birmingham Investigation Drug Services Pharmacy

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Moffitt Cancer Center at SouthShore

    Ruskin, Florida · Recruiting

  • Moffitt Cancer Center - International Plaza

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Moffitt McKinley Hospital

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center at Wesley Chapel

    Wesley Chapel, Florida · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory Children's Center

    Atlanta, Georgia · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Not yet recruiting

  • Northwestern University - Feinberg School of Medicine

    Chicago, Illinois · Not yet recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • The University of Kansas - Clinical Research Center

    Fairway, Kansas · Recruiting

  • The University of Kansas Hospital Cambridge North Tower A

    Kansas City, Kansas · Recruiting

  • The University of Kansas Hospital

    Kansas City, Kansas · Recruiting

  • The University of Kansas Medical Center Medical Office Building

    Kansas City, Kansas · Recruiting

  • The University of Kansas Hospital - Indian Creek Campus

    Overland Park, Kansas · Recruiting

  • The University of Kansas Cancer Center - Westwood

    Westwood, Kansas · Recruiting

  • MSK Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • MSK Monmouth

    Middletown, New Jersey · Recruiting

  • MSK Bergen

    Montvale, New Jersey · Recruiting

  • MSK Commack

    Commack, New York · Recruiting

  • MSK Westchester

    Harrison, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center 53rd street

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • 64th Street Outpatient and Innovation Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York · Recruiting

  • Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Upstate Specialty Services at Harrison Center

    Syracuse, New York · Recruiting

  • SUNY Upstate Medical University

    Syracuse, New York · Recruiting

  • SUNY Upstate Medical University-Community Campus

    Syracuse, New York · Recruiting

  • MSK Nassau

    Uniondale, New York · Recruiting

  • Biorepository and Precision Pathology Center (BRPC)

    Durham, North Carolina · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.